Skip to main content
Journal cover image

Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry.

Publication ,  Journal Article
Henderson, LA; Zurakowski, D; Angeles-Han, ST; Lasky, A; Rabinovich, CE; Lo, MS ...
Published in: Pediatr Rheumatol Online J
February 16, 2016

BACKGROUND: There is not yet a commonly accepted, standardized approach in the treatment of juvenile idiopathic uveitis when initial steroid therapy is insufficient. We sought to assess current practice patterns within a large cohort of children with juvenile uveitis. METHODS: This is a cross-sectional cohort study of patients with uveitis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRAnet) registry. Clinical information including, demographic information, presenting features, disease complications, and medications were collected. Chi-square and Fisher's exact tests were used to assess for associations between medications and clinical characteristics. RESULTS: Ninety-two children with idiopathic and 656 with juvenile idiopathic arthritis (JIA)-associated uveitis were identified. Indication (arthritis or uveitis) for medication use was not available for JIA patients; therefore, detailed analysis was limited to children with idiopathic uveitis. In this group, 94 % had received systemic steroids. Methotrexate (MTX) was used in 76 % of patients, with oral and subcutaneous forms given at similar rates. In multivariable analysis, non-Caucasians were more likely to be treated initially with subcutaneous MTX (P = 0.003). Of the 53 % of patients treated with a biologic DMARD, all received a tumor necrosis factor (TNF) inhibitor. TNF inhibitor use was associated with a higher frequency of cataracts (52 % vs 21 %; P = 0.001) and antinuclear antibody positivity (49 % vs 29 %; P = 0.04), although overall complication rates were not higher in these patients. CONCLUSION: Among idiopathic uveitis patients enrolled in the CARRAnet registry, MTX was the most commonly used DMARD, with subcutaneous and oral forms equally favored. Patients who received a TNF inhibitor were more likely to be ANA positive and have cataracts.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pediatr Rheumatol Online J

DOI

EISSN

1546-0096

Publication Date

February 16, 2016

Volume

14

Issue

1

Start / End Page

9

Location

England

Related Subject Headings

  • Uveitis
  • Rheumatology
  • Retrospective Studies
  • Registries
  • Methotrexate
  • Male
  • Infliximab
  • Humans
  • Follow-Up Studies
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Henderson, L. A., Zurakowski, D., Angeles-Han, S. T., Lasky, A., Rabinovich, C. E., Lo, M. S., & Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry  Investigators, . (2016). Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatr Rheumatol Online J, 14(1), 9. https://doi.org/10.1186/s12969-016-0069-5
Henderson, Lauren A., David Zurakowski, Sheila T. Angeles-Han, Andrew Lasky, C Egla Rabinovich, Mindy S. Lo, and Mindy S. Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry  Investigators. “Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry.Pediatr Rheumatol Online J 14, no. 1 (February 16, 2016): 9. https://doi.org/10.1186/s12969-016-0069-5.
Henderson LA, Zurakowski D, Angeles-Han ST, Lasky A, Rabinovich CE, Lo MS, et al. Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatr Rheumatol Online J. 2016 Feb 16;14(1):9.
Henderson, Lauren A., et al. “Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry.Pediatr Rheumatol Online J, vol. 14, no. 1, Feb. 2016, p. 9. Pubmed, doi:10.1186/s12969-016-0069-5.
Henderson LA, Zurakowski D, Angeles-Han ST, Lasky A, Rabinovich CE, Lo MS, Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry  Investigators. Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatr Rheumatol Online J. 2016 Feb 16;14(1):9.
Journal cover image

Published In

Pediatr Rheumatol Online J

DOI

EISSN

1546-0096

Publication Date

February 16, 2016

Volume

14

Issue

1

Start / End Page

9

Location

England

Related Subject Headings

  • Uveitis
  • Rheumatology
  • Retrospective Studies
  • Registries
  • Methotrexate
  • Male
  • Infliximab
  • Humans
  • Follow-Up Studies
  • Female